Journal of Clinical Endocrinology & Metabolism, Vol 81, 2968-2975, Copyright © 1996 by Endocrine Society

ARTICLES

A randomized, placebo-controlled trial of combined insulin-like growth factor I and low dose growth hormone therapy for wasting associated with human immunodeficiency virus infection [published erratum appears in J Clin Endocrinol Metab 1996 Oct;81(10):3696]

PD Lee, JM Pivarnik, JG Bukar, N Muurahainen, PS Berry, PR Skolnik, JL Nerad, KA Kudsk, L Jackson, KJ Ellis and N Gesundheit
Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA. phillipl@bcm.tmc.edu

Loss of body mass, or wasting, is a major cause of morbidity and a contributor to mortality in human immunodeficiency virus-1 (HIV-1) infection. Dietary supplements and appetite adjuvants have had limited effectiveness in treating this condition. GH and insulin-like growth factor I (IGF-I) have been shown to be anabolic in many catabolic conditions, and limited data suggest similar efficacy in HIV wasting. In addition, it appears that GH and IGF-I may have complementary anabolic effects with opposing glucoregulatory effects. We report results from a 12-week randomized, placebo-controlled trial of combination recombinant human GH (rhGH; Nutropin; 0.34 mg, sc, twice daily) and rhIGF-I (5.0 mg, sc, twice daily) in individuals with HIV wasting and without active opportunistic infection, cancer, or gastrointestinal disease. A total of 142 subjects (140 males and 2 females) were randomized using a 2:1, double blind treatment scheme and assigned to receive either active treatment or placebo injections. Eighty subjects completed the 12-week protocol. Nutritional intake and demographic and clinical characteristics did not differ between the groups at any study time point. At 3 weeks, the treatment group had a significantly larger weight increase (P = 0.0003), but this difference was not observed at any later time point. Similarly, fat-free mass, calculated from skinfold measurements, increased transiently in the treatment group at 6 weeks (P = 0.002). No significant differences in isokinetic muscle strength or endurance testing or in quality of life were observed between the groups. Resting heart rate was significantly higher in the treatment group at each time point post-baseline. GH and IGF-binding protein-3 levels did not change; however, IGF-I levels were higher in the treatment group at 6 and 12 weeks. There were no significant between-group differences in any of the measured biochemical or immunological parameters. rhGH plus rhIGF-I treatment was associated with an increased incidence of peripheral edema and other side-effects, possibly related to fluid retention. We conclude that the combination of rhIGF-I and low dose rhGH used in this study had no significant anabolic effect in HIV wasting.

This article has been cited by other articles:

				C. S. Fuchs, R. M. Goldberg, D. J. Sargent, J. A. Meyerhardt, B. M. Wolpin, E. M. Green, H. C. Pitot, and M. Pollak Plasma Insulin-like Growth Factors, Insulin-like Binding Protein-3, and Outcome in Metastatic Colorectal Cancer: Results from Intergroup Trial N9741 Clin. Cancer Res., December 15, 2008; 14(24): 8263 - 8269. [Abstract] [Full Text] [PDF]

				F. R Sattler, N. Rajicic, K. Mulligan, K. E Yarasheski, S. L Koletar, A. Zolopa, B. Alston Smith, R. Zackin, B. Bistrian, and for the ACTG 392 Study Team Evaluation of high-protein supplementation in weight-stable HIV-positive subjects with a history of weight loss: a randomized, double-blind, multicenter trial Am. J. Clinical Nutrition, November 1, 2008; 88(5): 1313 - 1321. [Abstract] [Full Text] [PDF]

				T. T. Perls, N. R. Reisman, and S. J. Olshansky Provision or Distribution of Growth Hormone for "Antiaging": Clinical and Legal Issues JAMA, October 26, 2005; 294(16): 2086 - 2090. [Full Text] [PDF]

				J. A. Meyerhardt, J. A. Sloan, D. J. Sargent, R. M. Goldberg, M. Pollak, R. F. Morton, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, and C. S. Fuchs Associations between Plasma Insulin-Like Growth Factor Proteins and C-Peptide and Quality of Life in Patients with Metastatic Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1402 - 1410. [Abstract] [Full Text] [PDF]

				K. Strle, S. R. Broussard, R. H. McCusker, W.-H. Shen, R. W. Johnson, G. G. Freund, R. Dantzer, and K. W. Kelley Proinflammatory Cytokine Impairment of Insulin-Like Growth Factor I-Induced Protein Synthesis in Skeletal Muscle Myoblasts Requires Ceramide Endocrinology, October 1, 2004; 145(10): 4592 - 4602. [Abstract] [Full Text] [PDF]

				V. ROELFSEMA and R. G. CLARK The Growth Hormone and Insulin-Like Growth Factor Axis: Its Manipulation for the Benefit of Growth Disorders in Renal Failure J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1297 - 1306. [Abstract] [Full Text]

				K. Mulligan, V. W. Tai, and M. Schambelan Use of Growth Hormone and Other Anabolic Agents in AIDS Wasting JPEN J Parenter Enteral Nutr, November 1, 1999; 23(6_suppl): S202 - S209. [Abstract] [PDF]

				C. Corcoran and S. Grinspoon Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome N. Engl. J. Med., June 3, 1999; 340(22): 1740 - 1750. [Full Text] [PDF]

				S. Jain, D. W. Golde, R. Bailey, and M. E. Geffner Insulin-Like Growth Factor-I Resistance Endocr. Rev., October 1, 1998; 19(5): 625 - 646. [Abstract] [Full Text]

				K. Mulligan, V. W. Tai, and M. Schambelan Effects of Chronic Growth Hormone Treatment on Energy Intake and Resting Energy Metabolism in Patients with Human Immunodeficiency Virus-Associated Wasting--A Clinical Research Center Study J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1542 - 1547. [Abstract] [Full Text]

				S. E. Mulroney, K. J. McDonnell, C. B. Pert, M. R. Ruff, Z. Resch, W. K. Samson, and M. D. Lumpkin HIV gp120 inhibits the somatotropic axis: A possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting PNAS, February 17, 1998; 95(4): 1927 - 1932. [Abstract] [Full Text] [PDF]